Biosafety directives and advisories
1) Biosafety directives
Biosafety directives provide regulated parties with the customized containment requirements for activities with a specific pathogen or group of pathogens when the containment level does not align with the risk group.
- Biosafety directive for New and Emerging Influenza A Viruses (17 August, 2018)
- Description of the minimum containment requirements for the safe handling of new and emerging influenza A viruses.
- Biosafety directive for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), and related simian retroviruses (1 June, 2017)
- Description of the minimum containment requirements for the safe handling of HIV, HTLV, and related simian retroviruses.
- Biosafety directive for Mycobacterium tuberculosis complex (MTBC) (10 March, 2017)
- Description of the minimum containment requirements for the safe handling of MTBC.
2) Biosafety advisories
Biosafety advisories are developed when the data obtained from a risk assessment of a new or emerging pathogen of interest indicates that new physical or operational requirements are required to work with the pathogen safely. The new operational and physical requirements need to be disseminated to interested parties as soon as possible.
- Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) (November 26, 2020)
- Zika Virus (April 14, 2016)
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (Updated July 7, 2015)
- Efficiently Transmissible Engineered Influenza A H5N1 Viruses: Biosafety Advisory (February 1, 2012)
Report a problem or mistake on this page
- Date modified: